At the news
? BULLISHIMPACT 6/10 DEFA14A filed Jun 26, 2026 at 17:24 ET
Apogee Therapeutics filed additional definitive proxy soliciting materials (DEFA14A) in support of its proposed acquisition by AbbVie, including a principal investigator email urging shareholder approval. The merger, announced on June 22, 2026, is expected to close in Q3 2026, subject to customary conditions including shareholder and regulatory approvals. This filing confirms management's active solicitation and commitment to the deal.
- Merger agreement with AbbVie dated June 18, 2026, via a merger subsidiary structure
- Transaction expected to close in Q3 2026, subject to shareholder approval and regulatory clearances
- Management is actively soliciting proxies in favor of the merger via a principal investigator email
- Apogee's lead asset is zumilokibart (APG777), a potential treatment for inflammatory and immunological conditions
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access